Research programme: gene editing therapeutics - CRISPR Therapeutics

Drug Profile

Research programme: gene editing therapeutics - CRISPR Therapeutics

Alternative Names: CRISPR-Cas9 gene therapies

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator CRISPR Therapeutics
  • Developer CRISPR Therapeutics; Genethon; Vertex Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cystic fibrosis; Duchenne muscular dystrophy; Haemoglobinopathies; Unspecified

Most Recent Events

  • 19 Dec 2016 CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics signs a global agreement on the foundational intellectual property for CRISPR/Cas9 gene editing technology
  • 08 Jun 2016 CRISPR Therapeutics and Anagenesis Biotechnologies enter into a strategic in-licensing and collaboration agreement to develop gene editing therapeutics for Duchenne muscular dystrophy
  • 08 Jun 2016 Early research in Duchenne muscular dystrophy in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top